Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955727 | 1.00 | GPR84 (0.56) | GPR84CYP2A6IDO1IMPDH2CCNT1 | |
| SCHEMBL15392978 | 0.93 | CYP2A6 (0.47) | GPR84CYP2A6IDO1IMPDH2CCNT1 | |
| SCHEMBL16727124 | 0.85 | CYP2A6 (0.53) | GPR84CYP2A6IMPDH2CCNT1CDK9 | |
| SCHEMBL186914 | 0.85 | CYP2A6 (0.53) | GPR84CYP2A6IDO1IMPDH2CCNT1 | |
| SCHEMBL29956600 | 0.85 | CYP2A6 (0.53) | GPR84CYP2A6IMPDH2CCNT1CDK9 | |
| SCHEMBL26705634 | 0.79 | CYP2A6 (0.56) | GPR84CYP2A6IDO1IMPDH2CCNT1 | |
| SCHEMBL15300960 | 0.79 | CYP2A6 (0.56) | CYP2A6IMPDH2CCNT1CDK9HASPIN | |
| SCHEMBL29956408 | 0.79 | CYP2A6 (0.47) | GPR84CYP2A6IMPDH2CCNT1CDK9 | |
| SCHEMBL2270998 | 0.79 | CYP2A6 (0.44) | GPR84CYP2A6IMPDH2CCNT1CDK9 | |
| SCHEMBL15331663 | 0.79 | ALDH1A1 (0.48) | CYP2A6IMPDH2CCNT1CDK9HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-19 | — | — | US | disclosed |
| CN-118591538-A | Pyrazinamide derivatives | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2722333-A1 | Spiro-indole derivatives for the treatment of parasitic diseases. | Novartis AG (CH) | 2014-04-23 | — | — | EP | disclosed |
| EP-2285808-B1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| CN-102015711-B | Spiro-indole derivatives for the treatment of parasitic diseases | NOVARTIS AG | 2013-05-01 | — | — | CN | disclosed |
| US-8399453-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-03-19 | — | — | US | disclosed |
| US-8399453-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-03-19 | — | — | US | disclosed |
| US-8399453-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-03-19 | — | — | US | disclosed |
| US-20110275613-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-10 | — | — | US | disclosed |
| WO-2009132921-A1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132921-A1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | GPR84 125/4885CYP2A6 202/4885IDO1 380/4885 |
| US-20090275560-A1 | ORGANIC COMPOUNDS | OTC, PC, OAT | GPR84 3128/4885CYP2A6 816/4885IDO1 536/4885 |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | SIRT5, GLS2, ARG2 | GPR84 1038/4885CYP2A6 1091/4885IDO1 1144/4885 |
| US-20110275613-A1 | ORGANIC COMPOUNDS | OTC, PC, OAT | GPR84 3092/4885CYP2A6 837/4885IDO1 550/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | GPR84 125/4885CYP2A6 202/4885IDO1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.